Rhabdomyosarcoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The essential laboratory tests for patients with rhabdomyosarcoma are evaluation of CBC, liver function tests, renal function tests, blood electrolytes, and coagulation studies. | The essential [[laboratory]] tests for [[patients]] with [[rhabdomyosarcoma]] are evaluation of [[CBC]], [[liver function tests]], [[renal function tests]], [[blood]] [[Electrolyte|electrolytes]], and [[coagulation]] studies. | ||
== Laboratory Findings== | == Laboratory Findings== | ||
* The essential laboratory tests for patients with rhabdomyosarcoma are:<ref name="pmid10466447">{{cite journal| author=Fiegl M, Weltermann A, Stindl R, Fonatsch C, Lechner K, Gisslinger H| title=Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature. | journal=Ann Hematol | year= 1999 | volume= 78 | issue= 7 | pages= 335-8 | pmid=10466447 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10466447 }} </ref><ref name="pmid9703006">{{cite journal| author=Kawasaki H, Takayama J, Nagasaki K, Yamaguchi K, Ohira M| title=Hypercalcemia in children with rhabdomyosarcoma. | journal=J Pediatr Hematol Oncol | year= 1998 | volume= 20 | issue= 4 | pages= 327-9 | pmid=9703006 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9703006 }} </ref> | * The essential [[laboratory]] tests for [[patients]] with [[rhabdomyosarcoma]] are:<ref name="pmid10466447">{{cite journal| author=Fiegl M, Weltermann A, Stindl R, Fonatsch C, Lechner K, Gisslinger H| title=Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature. | journal=Ann Hematol | year= 1999 | volume= 78 | issue= 7 | pages= 335-8 | pmid=10466447 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10466447 }} </ref><ref name="pmid9703006">{{cite journal| author=Kawasaki H, Takayama J, Nagasaki K, Yamaguchi K, Ohira M| title=Hypercalcemia in children with rhabdomyosarcoma. | journal=J Pediatr Hematol Oncol | year= 1998 | volume= 20 | issue= 4 | pages= 327-9 | pmid=9703006 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9703006 }} </ref> | ||
** CBC: | ** [[CBC]]: | ||
*** It may result into pancytopenia and anemia due to bone involvement. | *** It may result into [[pancytopenia]] and [[anemia]] due to [[bone]] involvement. | ||
** Liver function test ( LFT): | ** [[Liver function test]] ( [[LFT]]): | ||
*** LFT should be evaluated before | *** [[LFT]] should be evaluated before [[chemotherapy]] and for assessment of [[liver]] [[metastasis]]. | ||
** Renal function test: | ** [[Renal function tests|Renal function test]]: | ||
*** BUN and | *** [[BUN]] and [[creatinine]] levels should be evaluated before [[chemotherapy]]. | ||
** Blood electrolytes such as sodium, potassium, chlorine, calcium, phosphorous, and magnesium: | ** Blood [[Electrolyte|electrolytes]] such as [[sodium]], [[potassium]], [[chlorine]], [[calcium]], [[Phosphorous acid|phosphorous]], and [[magnesium]]: | ||
*** Hypercalcemia may occur. | *** [[Hypercalcemia]] may occur. | ||
*** These | *** These tests should be evaluated before [[chemotherapy]]. | ||
** Coagulation studies: | ** [[Coagulation]] studies: | ||
*** Disseminated intravascular coagulation may occur. | *** [[Disseminated intravascular coagulation]] may occur. | ||
Latest revision as of 16:56, 8 March 2019
|
Rhabdomyosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhabdomyosarcoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Rhabdomyosarcoma laboratory findings |
|
Risk calculators and risk factors for Rhabdomyosarcoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
The essential laboratory tests for patients with rhabdomyosarcoma are evaluation of CBC, liver function tests, renal function tests, blood electrolytes, and coagulation studies.
Laboratory Findings
- The essential laboratory tests for patients with rhabdomyosarcoma are:[1][2]
- CBC:
- It may result into pancytopenia and anemia due to bone involvement.
- Liver function test ( LFT):
- LFT should be evaluated before chemotherapy and for assessment of liver metastasis.
- Renal function test:
- BUN and creatinine levels should be evaluated before chemotherapy.
- Blood electrolytes such as sodium, potassium, chlorine, calcium, phosphorous, and magnesium:
- Hypercalcemia may occur.
- These tests should be evaluated before chemotherapy.
- Coagulation studies:
- Disseminated intravascular coagulation may occur.
- CBC:
References
- ↑ Fiegl M, Weltermann A, Stindl R, Fonatsch C, Lechner K, Gisslinger H (1999). "Massive disseminated intravascular coagulation and hyperfibrinolysis in alveolar rhabdomyosarcoma: case report and review of the literature". Ann Hematol. 78 (7): 335–8. PMID 10466447.
- ↑ Kawasaki H, Takayama J, Nagasaki K, Yamaguchi K, Ohira M (1998). "Hypercalcemia in children with rhabdomyosarcoma". J Pediatr Hematol Oncol. 20 (4): 327–9. PMID 9703006.